Which Drugmaker Did The Most Deals In 2010?
8 CommentsBy Ed Silverman // December 9th, 2010 // 9:24 am
Jeff Kinder, the freshly departed Pfizer ceo, may have been criticized for failing to buy smaller companies, but a recent tally shows Pfizer has, so far, this year been the biggest industry dealmaker, at least when it comes to individual products, according to Life Science Analytics. Pfizer struck 51 deals as October, inching past Sanofi-Aventis at 50 and Novartis at 49. Roche struck 46, Glaxo has done 44 and Bayer inked 31 deals. Rounding out the list was Teva at 30, AstraZeneca with 25, Abbott at 20 and Lilly with 18.
So what kind of deals? There were acquisitions; co-development deals; collaborations; co-marketing, co-promotion and commercialization; distribution and cross-distribution; cross licensing; development; licensing; manufacturing; supply agreements and sub-licensing. The showing is not terribly surprising, given that this now includes Wyeth. By contrast, last year Pfizer signed 20 deals and Wyeth inked 10.
Overall, big drugmakers have struck about 20 percent more deals in 2010 compared with last year as they venture into emerging markets, replenish pipelines and diversify into biologics and, in some cases, generics. The hot therapy areas for deals, by the way, continue to be oncology, which accounted for 24 percent, infectious diseases with 18 percent and central nervous system disorders at 14 percent. About 25 percent of the roughly 400 deals so far this year involved biologics, as opposed to small molecules. That contrasts with about 30 percent in 2006, when there were about 550 total deals.
pic thx to o5com on flickr
Eric
Where’s J&J on this list. I can’t believe that they did less than 18 deals in 2010, though they may have done them under a number of different entity names.
industry insider
Ed, does Pfizer’s total include the deals they made with Federal Prosecutors?
Sarah Terry
Johnson & Johnson did 18 deals so were tied for 10th place with Lilly as well as Merck & Co. Deals from all entity names were included. Sorry for the confusion.
Sarah Terry
Pfizer’s deals do include settlements, but not with Federal Prosecutors. The settlements included were those with other pharma/biotech players. That said, there were none for 2010 and only 1, with Matrix, in 2009.
Sam
Is there a table, chart, or some kind of reference for where these numbers came from? It would be interesting to delve deeper into the numbers a bit.
Sarah Terry
All of the data was pulled from the MedTRACK database, the world’s most comprehensive biomedical database covering companies, products, deals, venture and epidemiology. If you’d like, we can provide you a free trial and we can show you all of the detail behind the figures. My direct email is sterry@datamonitor.com. If you provide me your email I can send you some more data we put together with this analysis as well.
Nick
Did Astella Pharmaceutical co-develop or collaborate in 2010?
Sarah Terry
How do you differentiate the terms?